Antibody fragment-polymer conjugates and uses of same
    4.
    发明授权
    Antibody fragment-polymer conjugates and uses of same 有权
    抗体片段 - 聚合物缀合物及其用途

    公开(公告)号:US07842789B2

    公开(公告)日:2010-11-30

    申请号:US12291750

    申请日:2008-11-12

    IPC分类号: C07K16/00

    摘要: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.

    摘要翻译: 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物,其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比,缀合物显示出显着改善的循环中的半衰期,平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子(VEGF),人p185受体样酪氨酸激酶(HER2),人CD20,人CD18,人CD11a,人IgE,人凋亡受体-2(Apo-2),人 肿瘤坏死因子-α(TNF-α),人组织因子(TF),人α4和bgr7整合素,人GPIIb-IIIa整合素,人表皮生长因子受体(EGFR),人CD3和人白细胞介素-2受体α- 链(TAC)用于诊断和治疗应用。

    Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates
    6.
    发明申请
    Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates 有权
    使用抗TNF-α抗体片段 - 聚合物缀合物结合TNF-α的方法

    公开(公告)号:US20130084302A1

    公开(公告)日:2013-04-04

    申请号:US13372191

    申请日:2012-02-13

    IPC分类号: C07K17/02

    摘要: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.

    摘要翻译: 描述了通过共价连接到非蛋白质聚合物上的抗体片段形成的缀合物,其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比,缀合物显示出显着改善的循环中的半衰期,平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子(VEGF),人p185受体样酪氨酸激酶(HER2),人CD20,人CD18,人CD11a,人IgE,人凋亡受体-2(Apo-2),人 肿瘤坏死因子-α(TNF-α),人组织因子(TF),人α4和bgr7整合素,人GPIIb-IIIa整合素,人表皮生长因子受体(EGFR),人CD3和人白细胞介素-2受体α- 链(TAC)用于诊断和治疗应用。

    Antibody fragment-polymer conjugates and uses of same
    7.
    发明授权
    Antibody fragment-polymer conjugates and uses of same 有权
    抗体片段 - 聚合物缀合物及其用途

    公开(公告)号:US07214776B2

    公开(公告)日:2007-05-08

    申请号:US11259232

    申请日:2005-10-25

    IPC分类号: C07K16/00

    摘要: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.

    摘要翻译: 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物,其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比,缀合物显示出显着改善的循环中的半衰期,平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子(VEGF),人p185受体样酪氨酸激酶(HER2),人CD20,人CD18,人CD11a,人IgE,人凋亡受体-2(Apo-2),人 肿瘤坏死因子-α(TNF-α),人组织因子(TF),人α4β7整联蛋白,人GPIIb-IIIa整联蛋白,人表皮生长因子受体(EGFR),人CD3和人白细胞介素-2受体α链 TAC)用于诊断和治疗应用。

    Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates
    10.
    发明授权
    Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates 有权
    使用抗TNF-α抗体片段 - 聚合物缀合物结合TNF-α的方法

    公开(公告)号:US08652468B2

    公开(公告)日:2014-02-18

    申请号:US13372191

    申请日:2012-02-13

    IPC分类号: A61K39/395

    摘要: Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.

    摘要翻译: 描述了通过共价连接到非蛋白质聚合物上的抗体片段形成的缀合物,其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比,缀合物显示出显着改善的循环中的半衰期,平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子(VEGF),人p185受体样酪氨酸激酶(HER2),人CD20,人CD18,人CD11a,人IgE,人凋亡受体-2(Apo-2),人 肿瘤坏死因子-α(TNF-α),人组织因子(TF),人α4β7整联蛋白,人GPIIb-IIIa整联蛋白,人表皮生长因子受体(EGFR),人CD3和人白细胞介素-2受体α链 TAC)用于诊断和治疗应用。